Azitra reports ex vivo data showing repeat-dose penetration of filaggrin ingredient for anti-wrinkle program ATR-COSF

• Azitra reported ex vivo human skin studies supporting its ATR-COSF cosmetic program using an engineered S. epidermidis supernatant with rHDfilaggrin.
• Repeat-dose testing showed higher rHDfilaggrin delivery into the stratum granulosum versus prior single-dose work, with hydrogel formulation improving distribution.
• Elasticity rose dose-dependently at 20 hours, from 1.6x at 0.09% w/w to 4.4x at 7.5% w/w in hydrogel.
• A 0.28% w/w formulation restored elasticity to levels historically seen in healthy skin in the ex vivo abdominoplasty model.
• Safety testing under standardized guidelines found the 2% supernatant hydrogel non-irritating and non-corrosive to skin and eyes; human study planning continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033358), on July 15, 2026, and is solely responsible for the information contained therein.